BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

233 related articles for article (PubMed ID: 37470157)

  • 41. Rhizobium etli asparaginase II: an alternative for acute lymphoblastic leukemia (ALL) treatment.
    Huerta-Saquero A; Evangelista-Martínez Z; Moreno-Enriquez A; Perez-Rueda E
    Bioengineered; 2013; 4(1):30-6. PubMed ID: 22895060
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Bacterial l-asparaginases for cancer therapy: Current knowledge and future perspectives.
    Ghasemian A; Al-Marzoqi AH; Al-Abodi HR; Alghanimi YK; Kadhum SA; Shokouhi Mostafavi SK; Fattahi A
    J Cell Physiol; 2019 Nov; 234(11):19271-19279. PubMed ID: 30993718
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Minimal residual disease (MRD) measurement as a tool to compare the efficacy of chemotherapeutic drug regimens using Escherichia Coli-asparaginase or Erwinia-asparaginase in childhood acute lymphoblastic leukemia (ALL).
    Kwok CS; Kham SK; Ariffin H; Lin HP; Quah TC; Yeoh AE
    Pediatr Blood Cancer; 2006 Sep; 47(3):299-304. PubMed ID: 16302217
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [Therapeutic alternatives to native L-asparaginase in the treatment of adult acute lymphoblastic leukemia].
    Thomas X; Cannas G; Chelghoum Y; Gougounon A
    Bull Cancer; 2010 Sep; 97(9):1105-17. PubMed ID: 20693115
    [TBL] [Abstract][Full Text] [Related]  

  • 45. L-Asparagine depletion in plasma and cerebro-spinal fluid of children with acute lymphoblastic leukemia during subsequent exposures to Erwinia L-asparaginase.
    Gentili D; Conter V; Rizzari C; Tschuemperlin B; Zucchetti M; Orlandoni D; D'Incalci M; Masera G
    Ann Oncol; 1996 Sep; 7(7):725-30. PubMed ID: 8905031
    [TBL] [Abstract][Full Text] [Related]  

  • 46. L-asparaginase production review: bioprocess design and biochemical characteristics.
    Castro D; Marques ASC; Almeida MR; de Paiva GB; Bento HBS; Pedrolli DB; Freire MG; Tavares APM; Santos-Ebinuma VC
    Appl Microbiol Biotechnol; 2021 Jun; 105(11):4515-4534. PubMed ID: 34059941
    [TBL] [Abstract][Full Text] [Related]  

  • 47. A prospective study on drug monitoring of PEGasparaginase and Erwinia asparaginase and asparaginase antibodies in pediatric acute lymphoblastic leukemia.
    Tong WH; Pieters R; Kaspers GJ; te Loo DM; Bierings MB; van den Bos C; Kollen WJ; Hop WC; Lanvers-Kaminsky C; Relling MV; Tissing WJ; van der Sluis IM
    Blood; 2014 Mar; 123(13):2026-33. PubMed ID: 24449211
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Minimal effects of E. coli and Erwinia asparaginase on the coagulation system in childhood acute lymphoblastic leukemia: a randomized study.
    Risseeuw-Appel IM; Dekker I; Hop WC; Hählen K
    Med Pediatr Oncol; 1994; 23(4):335-43. PubMed ID: 8058004
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Prospective, real-time monitoring of pegylated Escherichia coli and Erwinia asparaginase therapy in childhood acute lymphoblastic leukaemia and non-Hodgkin lymphoma in Belgium.
    Mondelaers V; Ferster A; Uyttebroeck A; Brichard B; van der Werff Ten Bosch J; Norga K; Francotte N; Piette C; Vandemeulebroecke K; Verbeke C; Schmidt S; Benoit Y; Lammens T; De Moerloose B
    Br J Haematol; 2020 Jul; 190(1):105-114. PubMed ID: 32057100
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Therapeutic drug monitoring of asparaginase in the ALL-BFM 2000 protocol between 2000 and 2007.
    Schrey D; Borghorst S; Lanvers-Kaminsky C; Hempel G; Gerss J; Möricke A; Schrappe M; Boos J
    Pediatr Blood Cancer; 2010 Jul; 54(7):952-8. PubMed ID: 20108339
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Plasma asparaginase activity, asparagine concentration, and toxicity after administration of Erwinia asparaginase in children and young adults with acute lymphoblastic leukemia: Phase I/II clinical trial in Japan.
    Ogawa C; Taguchi F; Goto H; Koh K; Tomizawa D; Ohara A; Manabe A
    Pediatr Blood Cancer; 2017 Sep; 64(9):. PubMed ID: 28244643
    [TBL] [Abstract][Full Text] [Related]  

  • 52. ELISA to evaluate plasma anti-asparaginase IgG concentrations in patients with acute lymphoblastic leukemia.
    Wang B; Hak LJ; Relling MV; Pui CH; Woo MH; Storm MC
    J Immunol Methods; 2000 May; 239(1-2):75-83. PubMed ID: 10821949
    [TBL] [Abstract][Full Text] [Related]  

  • 53. L-asparaginase in the treatment of patients with acute lymphoblastic leukemia.
    Egler RA; Ahuja SP; Matloub Y
    J Pharmacol Pharmacother; 2016; 7(2):62-71. PubMed ID: 27440950
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Asparaginase (Erwinia chrysanthemi) (Recombinant)-rywn.
    Am J Health Syst Pharm; 2021 Oct; 78(21):1919-1921. PubMed ID: 34492097
    [No Abstract]   [Full Text] [Related]  

  • 55. Prognostic significance of early response to a single dose of asparaginase in childhood acute lymphoblastic leukemia.
    Asselin BL; Kreissman S; Coppola DJ; Bernal SD; Leavitt PR; Gelber RD; Sallan SE; Cohen HJ
    J Pediatr Hematol Oncol; 1999; 21(1):6-12. PubMed ID: 10029805
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Proteins from Erwinia asparaginase Erwinase ® and E. coli asparaginase 2 MEDAC ® for treatment of human leukemia, show a multitude of modifications for which the consequences are completely unclear.
    Bae N; Pollak A; Lubec G
    Electrophoresis; 2011 Jul; 32(14):1824-8. PubMed ID: 21769889
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Pharmacological and clinical monitoring in children with acute lymphoblastic leukemia treated with a biogeneric PEG-l-asparaginase product.
    Matteo C; Colombini A; Bettini LR; Porcu L; Barzaghi S; Ceruti T; Silvestri D; Amoroso A; Dell'Acqua F; Gotti G; Nastasi C; Zucchetti M; Rizzari C
    Pediatr Blood Cancer; 2022 Sep; 69(9):e29753. PubMed ID: 35561075
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Beta-aspartylpeptides as substrates of L-asparaginases from Escherichia coli and Erwinia chrysanthemi.
    Kelo E; Noronkoski T; Stoineva IB; Petkov DD; Mononen I
    FEBS Lett; 2002 Sep; 528(1-3):130-2. PubMed ID: 12297292
    [TBL] [Abstract][Full Text] [Related]  

  • 59. What makes a good new therapeutic L-asparaginase?
    Beckett A; Gervais D
    World J Microbiol Biotechnol; 2019 Sep; 35(10):152. PubMed ID: 31552479
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Measurement of subvisible particulates in lyophilised Erwinia chrysanthemi L-asparaginase and relationship with clinical experience.
    Gervais D; Corn T; Downer A; Smith S; Jennings A
    AAPS J; 2014 Jul; 16(4):784-90. PubMed ID: 24854894
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.